Duloxetine
- Generic Name
- Duloxetine
- Brand Names
- Cymbalta, Drizalma, Irenka, Yentreve, Duloxetine Zentiva, Duloxetine Mylan, Duloxetine Lilly
- Drug Type
- Small Molecule
- Chemical Formula
- C18H19NOS
- CAS Number
- 116539-59-4
- Unique Ingredient Identifier
- O5TNM5N07U
- Background
Duloxetine is a dual serotonin and norepinephrine reuptake inhibitor. It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686. Duloxetine first received approval from the FDA in August, 2004 as Cymbalta for the treatment of Major Depressive Disorder. It has since received approval for a variety of indications including the tre...
- Indication
Indicated for:
1) Management of Major Depressive Disorder.
2) Management of Generalized Anxiety Disorder.
3) Management of diabetic peripheral neuropathy.
4) Management of fibromyalgia.
5) Management of chronic musculoskeletal pain.
6) Management of osteoarthritis of the knee in adults.
7) Management of chronic lower back pain in adults.
...
- Associated Conditions
- Chronic Lower Back Pain (CLBP), Chronic Musculoskeletal Pain, Diabetic Peripheral Neuropathic Pain (DPN), Fibromyalgia, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Osteoarthritis of the Knee, Stress Urinary Incontinence (SUI)
- Associated Therapies
- -
Study Evaluating the Effects of DVS SR and Duloxetine on the Pharmacokinetics of Desipramine in Healthy Subjects
- Conditions
- First Posted Date
- 2006-08-21
- Last Posted Date
- 2007-05-28
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 20
- Registration Number
- NCT00366652
Identifying Factors That Predict Antidepressant Treatment Response
- Conditions
- Interventions
- First Posted Date
- 2006-08-04
- Last Posted Date
- 2016-08-30
- Lead Sponsor
- Emory University
- Target Recruit Count
- 344
- Registration Number
- NCT00360399
- Locations
- 🇺🇸
Emory University School of Medicine, Atlanta, Georgia, United States
🇺🇸Emory University Mood and Anxiety Disorders Program, Atlanta, Georgia, United States
Efficacy of Seroquel SR in Combination With an Antidepressant in Treatment of Major Depressive Disorder
- Conditions
- First Posted Date
- 2006-07-13
- Last Posted Date
- 2011-01-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 494
- Registration Number
- NCT00351910
- Locations
- 🇸🇪
Research Site, Uppsala, Sweden
Pilot Study of Duloxetine in Psychological Resilience
- First Posted Date
- 2006-05-31
- Last Posted Date
- 2013-08-02
- Lead Sponsor
- Duke University
- Target Recruit Count
- 18
- Registration Number
- NCT00331799
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
Maintenance of Effect of Duloxetine in Patients With Diabetic Peripheral Neuropathic Pain (DPNP)
- First Posted Date
- 2006-05-08
- Last Posted Date
- 2011-02-07
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 216
- Registration Number
- NCT00322621
- Locations
- 🇮🇹
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rome, Italy
Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo and Active Control in Major Depressive Disorder
- Conditions
- First Posted Date
- 2006-05-03
- Last Posted Date
- 2009-03-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 600
- Registration Number
- NCT00321490
- Locations
- 🇺🇸
Research Site, Morgantown, West Virginia, United States
A Pilot Study Assessing Duloxetine's Efficacy in Atypical Depression
- Conditions
- First Posted Date
- 2006-02-27
- Last Posted Date
- 2008-01-15
- Lead Sponsor
- New York State Psychiatric Institute
- Target Recruit Count
- 20
- Registration Number
- NCT00296699
- Locations
- 🇺🇸
Depression Evaluation Service - New York State Psychiatric Institute, New York, New York, United States
Duloxetine Versus Placebo in the Treatment of FMS
- Conditions
- First Posted Date
- 2005-10-05
- Last Posted Date
- 2007-08-23
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 320
- Registration Number
- NCT00233025
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London, United Kingdom
Treatment of MDEs During the Course of Psychotic Disorders With Duloxetine
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2008-06-04
- Lead Sponsor
- Central Institute of Mental Health, Mannheim
- Target Recruit Count
- 20
- Registration Number
- NCT00224302
- Locations
- 🇩🇪
Central Institute of Mental Health, Department of Psychiatry,, Mannheim, BW, Germany
Effectiveness and Safety of Duloxetine in Women Experiencing Urinary Leakage Due to Physical Stress and Urge.
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2007-01-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 600
- Registration Number
- NCT00190814
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, please call 1-877-CTLILLY(1-877-285-4559, 1-317-615-4559), Monday-Friday, 9 am to 5 pm Eastern time (UTC/GMT - 5 hours, EST) or speak with your personal physician, London, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.